NBT-NM108 as an Early Treatment for Suspected or Confirmed Symptomatic COVID-19 Patients
Phase 2
Completed
- Conditions
- Suspected or Confirmed COVID-19
- Interventions
- Other: Usual Care Only
- First Posted Date
- 2020-09-07
- Last Posted Date
- 2024-10-07
- Lead Sponsor
- Notitia Biotechnologies Company
- Target Recruit Count
- 42
- Registration Number
- NCT04540406
- Locations
- 🇺🇸
University of South Florida Morsani College of Medicine, Tampa, Florida, United States
© Copyright 2025. All Rights Reserved by MedPath